Polydex Pharmaceuticals (POLXF) 10-Q 2002 Q3 Quarterly report

QuickLinks -- Click here to rapidly navigate through this document

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

/x/
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 31, 2001

or

/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to              

Commission File Number 1-8366

POLYDEX PHARMACEUTICALS LIMITED
(Exact Name of Registrant as Specified in Its Charter)

Commonwealth of the Bahamas	None
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)
421 Comstock Road, Toronto, Ontario, Canada	M1L 2H5
(Address of Principal Executive Offices)	(Zip Code)
Registrant's Telephone Number, Including Area Code(416) 755-2231
Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report

    Indicate by check whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes /x/  No / /

    Indicate the number of shares outstanding of each of the issuer's classes of common shares, as of the latest practicable date.

Common Shares, $.0167 Par Value	3,047,368 shares
(Title of Class)	(Outstanding at December 11, 2001)

POLYDEX PHARMACEUTICALS LIMITED
TABLE OF CONTENTS

		Page
PART I	FINANCIAL INFORMATION
Item 1	CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Consolidated Balance Sheets October 31, 2001 and January 31, 2001	3
	Consolidated Statements of Operations Three months ended October 31, 2001 and 2000 Nine months ended October 31, 2001 and 2000	5
	Consolidated Statements of Shareholders' Equity and Comprehensive Income Nine months ended October 31, 2001 and 2000	6
	Consolidated Statements of Cash Flows Nine months ended October 31, 2001 and 2000	7
	Segmented Information Three months ended October 31, 2001 and 2000 Nine months ended October 31, 2001 and 2000	8
	Notes to Consolidated Financial Statements (Unaudited)	9
Item 2	MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	10
Item 3	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	14
PART II	OTHER INFORMATION
Item 6	EXHIBITS AND REPORTS ON FORM 8-K	16
	Signatures	17

2

PART I
FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements (unaudited).

POLYDEX PHARMACEUTICALS LIMITED

Consolidated Balance Sheets
(Expressed in United States dollars)

			(Unaudited) October 31, 2001		January 31, 2001
Assets
Current assets:
	Cash		$	327,233	$	403,203
	Trade accounts receivable			1,123,143		1,138,872
	Inventories:
		Finished goods		1,870,468		1,567,518
		Work in process		62,605		33,037
		Raw materials		500,878		606,082
	Inventories			2,433,951		2,206,637
	Prepaid expenses and other current assets			48,987		82,832
				3,933,314		3,831,544
Property, plant and equipment, net				4,667,755		5,064,084
Patents, net				114,791		131,428
Due from Sparhawk Laboratories, Inc.				131,640		138,247
Due from shareholder				1,159,876		1,251,200
Deferred income taxes				648,876		781,764
Other assets				18,449		19,059
			$	10,674,701	$	11,217,326

3

				(Unaudited) October 31, 2001			January 31, 2001
Liabilities and Shareholders' Equity
Current liabilities:
	Bank indebtedness			$	154,231		$	—
	Accounts payable				1,148,025			951,597
	Accrued liabilities				627,818			630,223
	Customer deposits received				45,368			85,227
	Income taxes payable				68,056			4,657
	Current portion of long-term debt				264,185			388,812
	Current portion of capital lease obligations				72,749			131,515
					2,380,432			2,192,031
Long-term debt					724,839			844,701
Capital lease obligations					384,175			464,737
Due to shareholder					687,837			722,222
Total liabilities					4,177,283			4,223,691
Shareholders' equity:
	Capital stock
		Authorized:
			100,000 Class A preferred shares, par value $0.10 per share 899,400 Class B preferred shares, par value $0.0167 per share 10,000,000 common shares, par value $0.0167 per share
		Issued and outstanding:
			899,400 Class B preferred shares		15,010			15,010
			3,047,603 common shares (2001—3,027,477)		50,434			50,434
	Contributed surplus				23,224,128			23,221,104
	Deficit				(15,611,998	)		(15,397,648	)
	Accumulated other comprehensive income				(1,180,156	)		(895,265	)
					6,497,418			6,993,635
				$	10,674,701		$	11,217,326

4

POLYDEX PHARMACEUTICALS LIMITED

Consolidated Statements of Operations (Unaudited)
(Expressed in United States dollars)

			Actual Quarter Ended October 31, 2001		Actual Quarter Ended October 31, 2000		Actual Year to Date October 31, 2001			Actual Year to Date October 31, 2000
Sales			$	3,126,682	$	4,053,774	$	9,072,062		$	10,552,501
Cost of products sold				2,317,241		3,027,483		6,964,689			7,746,123
				809,441		1,026,291		2,107,373			2,806,378
Other Revenue				—		182,400		—			182,400
Expenses:
	General and administrative			447,618		408,630		1,269,491			1,232,882
	Depreciation			134,542		149,494		394,755			431,992
	Research and development			87,442		348,635		294,560			706,744
	Interest expense			50,778		73,915		163,064			224,703
	Selling and promotion			40,568		40,447		104,558			121,994
	Amortization			5,546		5,546		16,637			16,637
				766,494		1,026,667		2,243,065			2,734,952
Income (loss) from operations				42,947		182,024		(135,692	)		253,826
Other income (loss):
	Gain (loss) on sale of equipment			187		—		(27,444	)		—
	Interest and other			67,299		5,004		145,101			25,534
				67,486		5,004		117,657			25,534
Income (loss) before the undernoted				110,433		187,028		(18,035	)		279,360
Provision for income taxes				110,384		124,727		196,315			291,739
Net income (loss) for the period			$	49	$	62,301	$	(214,350	)	$	(12,379	)
Per share information:
	Earnings (loss) per common share for the period:
		Basic	$	0.00	$	0.02	$	(0.07	)	$	(0.00	)
		Diluted	$	0.00	$	0.02	$	(0.07	)	$	(0.00	)
Weighted average number of common shares outstanding for the period				3,037,540		3,030,717		3,032,509			3,026,942

5

POLYDEX PHARMACEUTICALS LIMITED

Consolidated Statements of Shareholders' Equity and Comprehensive Income (Unaudited)
(Expressed in United States dollars)

		Year to Date October 31, 2001			Year to Date October 31, 2000
Preferred Shares:
	Balance, beginning of period	$	15,010		$	15,010
	Private placement of preferred shares		—			—
	Balance, end of period	$	15,010		$	15,010
Common Shares:
	Balance, beginning of period	$	50,434		$	50,203
	Common share options exercised		—			147
Balance, end of period		$	50,434		$	50,350
Contributed Surplus:
	Balance, beginning of period	$	23,221,104		$	23,121,345
	Common share options exercised		—			29,740
	Common share options granted		3,024			18,000
	Balance, end of period	$	23,224,128		$	23,169,085
Deficit:
	Balance, beginning of period	$	(15,397,648	)	$	(15,528,932	)
	Net loss for the period		(214,350	)		(12,379	)
	Balance, end of period	$	(15,611,998	)	$	(15,541,311	)
Accumulated Other Comprehensive Income:
	Balance, beginning of period	$	(895,265	)	$	(692,992	)
	Currency translation adjustment for the period		(284,891	)		(161,902	)
	Balance, end of period	$	(1,180,156	)	$	(854,894	)
Comprehensive Income for the period:
	Net loss for the period	$	(214,350	)	$	(12,379	)
	Currency translation adjustment for the period		(284,891	)		(161,902	)
		$	(499,241	)	$	(174,281	)

6

POLYDEX PHARMACEUTICALS LIMITED

Consolidated Statements of Cash Flows (Unaudited)
(Expressed in United States dollars)

			October 31, 2001			October 31, 2000
Cash provided by (used in):
Operating activities:
	Net loss for the period		$	(214,350	)	$	(12,379	)
	Add (deduct) items not affecting cash:
		Depreciation and amortization		411,392			448,629
		Imputed interest on long-term debt		44,847			62,437
		Deferred income taxes		108,374			238,159
		Loss on sale of equipment		27,444			—
		Options issued in exchange for services provided		3,024			18,000
	Change in non-cash operating working capital			(7,681	)		(247,118	)
				373,050			507,728
Investing activities:
	Additions to property, plant and equipment and patents			(306,882	)		(521,102	)
	Repayment of due from shareholder, net			91,324			15,221
	Repayment from Sparhawk Laboratories, Inc.			6,607			—
	Proceeds from sale of equipment			110,000			—
				(98,951	)		(505,881	)
Financing activities:
	Proceeds from long-term debt			—			49,896
	Repayment of long-term debt			(286,990	)		(448,937	)
	Repayment of capital lease obligations			(109,261	)		(85,727	)
	Increase (decrease) in due to shareholder			(34,385	)		37,412
	Increase in bank indebtedness			154,231			85,784
	Exercise of common share options			—			29,887
				(276,405	)		(331,685	)
	Effect of exchange rate changes on cash			(73,663	)		6,555
Decrease in cash position				(75,970	)		(323,283	)
Cash, beginning of period				403,203			799,565
Cash, end of period			$	327,233		$	476,282

7

POLYDEX PHARMACEUTICALS LIMITED

Segmented Information (Unaudited)
(Expressed in United States dollars)

    All operations are carried out through Dextran Products Limited ("Dextran") in Canada and through Chemdex, Inc. ("Chemdex") in the United States. The operations of Chemdex represent the veterinary products business and the operations are carried out through its wholly-owned subsidiary, Veterinary Laboratories, Inc. Each of Dextran and Chemdex operates as a strategic business unit offering different products. Each subsidiary comprises a reportable segment as follows:

Dextran—	manufactures and sells bulk quantities of Dextran and several of its derivatives to large pharmaceutical companies throughout the world.
Veterinary products—	manufactures and sells veterinary pharmaceutical products and specialty chemicals in the United States. The primary customers are distributors and private labelers, who in turn sell to the end-user of these products.

		Quarter Ended October 31, 2001		Quarter Ended October 31, 2000		Year to Date October 31, 2001			Year to Date October 31, 2000
Sales:
	Dextran	$	1,142,717	$	1,295,709	$	3,457,076		$	3,849,833
	Veterinary products		2,021,178		2,886,175		5,853,311			7,062,198
	Total segment sales		3,163,895		4,181,884		9,310,387			10,912,031
	Less: intercompany sales elimination		37,213		128,110		238,325			359,530
	Total consolidated sales	$	3,126,682	$	4,053,774	$	9,072,062		$	10,552,501
Income (loss) from operations:
	Dextran	$	211,260	$	118,097	$	503,830		$	493,682
	Veterinary products		3,045		357,310		(18,749	)		519,102
	Total income from operations from segments		214,305		475,407		485,081			1,012,784
	Less: Unallocated corporate expenses		171,358		293,383		620,773			758,958
	Total consolidated income (loss) from operations	$	42,947	$	182,024	$	(135,692	)	$	253,826
Assets:
	Dextran					$	5,177,474		$	5,509,822
	Veterinary products						4,293,312			4,398,928
	Total assets from segments						9,470,786			9,908,750
	Corporate assets						1,203,915			1,395,884
	Total consolidated assets					$	10,674,701		$	11,304,634

8

1.  Basis of Presentation:

    The information contained in the interim consolidated financial statements is condensed from that which would appear in the annual consolidated financial statements. Accordingly, the interim consolidated financial statements included herein should be read in conjunction with the January 31, 2001 Annual Report on Form 10-K filed by Polydex Pharmaceuticals Limited (the "Company"). The unaudited interim consolidated financial statements as of October 31, 2001 and 2000 include all normal recurring adjustments which management considers necessary for a fair presentation. The results of operations for the interim periods are not necessarily indicative of the results that may be expected for the entire fiscal year. The interim consolidated financial statements include the accounts and transactions of the Company and its majority owned subsidiaries in which the Company has more than a 50% ownership interest and exercises control.

9

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

    The Company's fiscal year ends on January 31st therefore fiscal year 2002 refers to the Company's year ended January 31, 2002. The following discussion should be read in conjunction with the financial statements and notes thereto included elsewhere in this report.

(a) Results of Operations

    The operations of the Company are carried on through Dextran Products Limited ("Dextran Products") in Canada and through Chemdex, Inc. ("Chemdex") in the United States. The operations of Chemdex are carried on through its wholly-owned subsidiary, Veterinary Laboratories, Inc. ("Vet Labs"). Each of Dextran Products and Vet Labs operates as a strategic business unit. Dextran Products manufactures and sells bulk quantities of Dextran and several of its derivatives to large pharmaceutical companies throughout the world. Vet Labs manufactures and sells veterinary pharmaceutical products and specialty chemicals in the United States. The primary customers are distributors and private labelers, who in turn sell to the end-user of these products.

    Net income for the third quarter ended October 31, 2001 amounted to $49 or $0 per share as compared to net income of $62,301 or $0.02 per share for the third quarter ended October 31, 2000. This decline in results is attributable to the decline in sales and operating profits at Vet Labs during the quarter. Last year Vet Labs had a strong third quarter, but the slowing United States economy and the surplus of beef resulted in significantly decreased sales in the third quarter of this year.

    During the third quarter ended October 31, 2001, the Registrant's income from operations amounted to $42,947 or $0.01 per share, as compared to income from operations of $182,024 or $0.06 per share for the third quarter of fiscal 2001, ending October 31, 2000. This decline in results is primarily due to a decrease in operating profits at Vet Labs of $354,265 offset by an increase in operating profits at Dextran Products of $93,163 and a reduction of corporate expenses of $122,025. The increase in operating profits at Dextran Products is primarily attributable to the increase in margins and the decreased research and development expenses as compared to the same quarter last year. The decrease in operating profits at Vet Labs is primarily attributable to a large decrease in sales and margins during the quarter as compared to the same quarter last year.

    Sales volume for the third quarter of fiscal 2002 decreased from $4,053,774 to $3,126,682, representing a decrease of $927,092 or 23%. Vet Labs experienced a quarter over quarter decrease in sales of $864,997 or 30% due to significantly decreased sales in the injectable product line. Injectable Iron Dextran and the vitamin products have experienced the largest declines in the injectable product line. Injectable Iron Dextran sales are down due to customer overstocking at the distribution level and the market penetration of a competing 200mg Iron Injection product into the Vet Labs historic 100mg markets. Sales of all injectable products, including the vitamin products, are down due to reduced demand for beef and the reduction in cattle prices. The slowdown in the United States economy has resulted in reduced business and pleasure travel and reduced restaurant spending, particularly at the high end. This has resulted in a surplus of beef. Farmers have reacted by reducing cattle herds, which reduces the demand for injectable products.

    Sales at Dextran Products decreased by $152,992 or 12% as compared to the same quarter in fiscal 2001. This decrease in sales at Dextran Products is primarily due to a longer than normal summer maintenance shutdown in the third quarter of fiscal 2002. In fiscal 2002, the summer maintenance shutdown was almost three weeks long, as opposed to the typical two-week period, to allow for additional equipment maintenance and repairs. Maintenance and repairs were successfully completed. In fiscal 2001, the summer maintenance shutdown was only one week long because certain maintenance was performed in the fourth quarter of fiscal 2000 during the plant shutdown for equipment installation.

10

    Gross margins increased from 25% in the third quarter of fiscal 2001 to 26% in the third quarter of fiscal 2002. Dextran Products' quarter over quarter gross margin increased from 31% in the third quarter of fiscal 2001 to 46% during the third quarter of fiscal 2002. Vet Labs' gross margin decreased from 22% in the third quarter of fiscal 2001 to 13% in the third quarter of fiscal 2002. The margin increase at Dextran Products is primarily a result of the significant decrease in the value of the Canadian dollar relative to the United States dollar. Dextran Products' sales are primarily denominated in United States dollars while the majority of the cost of sales is incurred in Canadian dollars. The margin decrease at Vet Labs is a result of the decreased sales in the injectables product line. This is the higher margin product line. The lower than normal sales resulted in higher average costs for fixed manufacturing overheads, as the fixed costs did not change.

    Management expects sales and margins to continue at approximately current levels at Dextran Products. Management expects sales levels in the fourth quarter of fiscal 2002 at Vet Labs to be below the sales levels in the fourth quarter of fiscal 2001 because of the continuing decline in the United States economy. The events of September 11 have resulted in further reducing travel which impacts restaurant spending. The full effects of this decline in travel will likely be felt in the fourth quarter of fiscal 2002 and the first quarter of fiscal 2003. Management expects to see a turnaround commencing in the second quarter of fiscal 2003 when the general economic conditions in the United States are expected to begin improving.

    General and administrative expenses in the third quarter of fiscal 2002 increased by $38,988 or 10% from the third quarter of fiscal 2001 due primarily to increases in professional fees at Vet Labs. Year to date general and administrative expenses, in fiscal 2002, are relatively consistent with the level of expenses incurred in the same period in fiscal 2001. Depreciation and amortization in the third quarter of fiscal 2002 decreased by $14,952 or 10% from the third quarter of fiscal 2001 due primarily to the reduced capital expenditures and certain equipment becoming fully depreciated. Selling and promotion expenses in the third quarter of fiscal 2002 were consistent with the same period in the prior year.

    Due to sustained funding by research and development partners, research and development costs in the third quarter of fiscal 2002 decreased by $294,905 or 85% as compared to the third quarter of fiscal 2001. Although funding from all sources for these research and development projects will continue, the Company's portion of these costs will not need to be increased for the remainder of the year.

    Research and development, in conjunction with the Consortium for Industrial Collaboration in Contraceptive Research (CICCR) and the Rush Medical Center in Chicago, relating to Cellulose Sulfate gel is progressing. Pre-IND tests have indicated that this gel holds great promise as a topical prophylactic for sexually transmitted diseases, including AIDS, and as a contraceptive. Two Phase I human clinical trials to test the safety and tolerance of this gel were successfully completed. These trials were funded by CICCR. The project team is moving ahead to put the supply chain in place for long-term toxicology and further clinical trials. Management expects funding to continue from CICCR for this project.

    The Company licensed the cystic fibrosis product, Usherdex, to BCY Lifesciences of Vancouver, British Columbia. Under this license agreement, BCY Lifesciences will provide funding for research and development and will pay a royalty to the Company based on sales and sublicensing revenue in return for the exclusive right to sublicense, manufacture, distribute and sell the product or products developed. BCY Lifesciences filed an Investigative New Drug application in Canada to seek approval to conduct a Phase I clinical trial, during the second quarter of fiscal 2002. BCY Lifesciences is completing preparations for the Phase I clinical trial. In anticipation of successful Phase I human clinical testing, BCY Lifesciences is already planning to commence Phase II clinical trials in the first half of fiscal 2003.

11

    Interest expense in the third quarter of fiscal 2002 decreased by $23,137 or 31% as compared to the third quarter in fiscal 2001 due to the repayment of long-term debt and capital lease obligations. In addition, interest expense, during the third quarter of fiscal 2002, includes imputed interest on both the share value guarantee payable, resulting from the acquisition of Vet Labs in 1992, and the lawsuit settlement payable, totaling $13,457.

    Interest and other income in the third quarter of fiscal 2002 increased by $62,295 or 1,245% as compared to the third quarter of fiscal 2001 due to the foreign exchange gain realized by Dextran Products.

    The Foot and Mouth disease problem in Europe appears to be of little impact to the Company. Dextran Products continues to be in contact with its agents overseas and to date the problem does not seem to have had a noticeable impact. Feedback from Asia, Europe and the United States shows limited effect to date. The impact of the Foot and Mouth disease problem has also had minimal impact on Vet Labs. Additionally, the mad cow disease problem in Europe has had minimal impact on the Company.

    The raw material supplier of Pentobarbital used in euthanasia product, for Vet Labs, appears to have resolved their regulatory problems with their production. Vet Labs began to receive shipments of Pentobarbital during the quarter allowing for production of euthanasia product. Management expects future sales of these products to return to normal historic levels. Sales of euthanasia products in the third quarter of fiscal 2002 amounted to $56,960, as compared to no sales in the third quarter of fiscal 2001.

    Operating results for the third quarter ended October 31, 2001 are not necessarily indicative of the results that may be expected for the year ended January 31, 2002. For further information, refer to the consolidated statements and footnotes thereto included in the Registrant's annual report on Form 10-K for the year ended January 31, 2001.

(b) Liquidity and Capital Resources

    The Registrant, in the third quarter of fiscal 2002, generated cash flow from operations of $411,416 compared to cash flow from operations of $19,039 in the third quarter of fiscal 2001. This increase of $392,377 or 2,061% is primarily attributable to the decrease in non-cash working capital during the quarter. The decrease in non-cash working capital levels, during the third quarter of 2002, resulted from decreases in trade accounts receivable.

    At October 31, 2001, the Company had trade accounts receivable of $1,123,143 and $2,433,951 in inventory compared to $1,406,074 and $2,340,395, respectively, at July 31, 2001. The decrease in trade accounts receivable during the third quarter of fiscal 2002 was due to timing of sales and collections at quarter-end. The inventory levels were increased at Dextran Products during the third quarter of fiscal 2002 in anticipation of sales volume in the fourth quarter. Inventory levels at Vet Labs were decreased due to the lower sales volumes experienced in fiscal 2002.

    There were no significant changes in financing or investing activities and there were no significant capital expenditures during the third quarter of 2002.

    The reduction in the accumulated other comprehensive income, of $189,553 during the third quarter of fiscal 2002, is entirely attributable to the currency translation adjustment of Dextran Products. Dextran Products' functional currency is the Canadian dollar. This currency translation adjustment arises from the translation of Dextran Products' financial statements to U.S. dollars.

    Dextran Products has a CDN$750,000 (US$500,000) line of credit, of which $81,931 was utilized at October 31, 2001. Management anticipates using the credit line for the purposes of funding a portion of the costs associated with the refurbishment of the Toronto facility. The Vet Labs—Sparhawk Joint

12

Venture has a $75,000 line of credit to fund operations, of which $72,300 was utilized at October 31, 2001. Vet Labs has a loan commitment for $400,000 to be used for building construction. Management is not planning any construction at Vet Labs during fiscal 2002, and therefore does not expect to borrow any funds under this loan commitment during fiscal 2002.

    Management expects the primary source of its future capital needs to be a combination of company earnings and borrowings. The Company, at present, does not have any material commitments for capital expenditures, although management intends to continue the plant refurbishment at Dextran Products.

    No changes in accounting principles or their application have been implemented in the reporting period that would have a material effect on reported income. Changes in the relative values of the Canadian dollar and the U.S. dollar occur from time to time and may, in certain instances, materially affect the Company's results of operations.

    The Company does not believe that the impact of inflation and changing prices on its operations are material.

Long-term Objectives

    At the beginning of the year, two critical long-term objectives were identified.

1.

Bring new products to market. During the third quarter, development work has continued on the cellulose sulfate project and Usherdex. Vet Labs is continuing development of new veterinary products.

2.

Upgrade and refurbish existing production facilities to increase capacity and efficiency. Refurbishment of the Dextran Products plant is continuing and planning for the next two phases is nearing completion. Management is planning to install a rotary drum vacuum filter machine and a fermenter during the winter maintenance shutdown in December, 2001.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

    This Form 10-Q, including the Management's Discussion and Analysis of Financial Condition and Results of Operations, contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs concerning future events, including, but not limited to statements regarding management's expectations of regulatory approval and the commencement of sales. In addition, statements containing expressions such as "believes", "anticipates", "plans" or "expects" used in this Form 10-Q, the Company's Annual Report, and the Company's periodic reports on Forms 10-K and 10-Q previously filed with the Securities and Exchange Commission are intended to identify forward-looking statements. The Company cautions that these and similar statements in this Form 10-Q, the Company's Annual Report, and in previously filed periodic reports including reports filed on Forms 10-K and 10-Q are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, changing market conditions, the progress of clinical trials, and the results obtained, the establishment of new corporate alliances, the impact of competitive products and pricing, and the timely development, FDA approval and market acceptance of the Company's products, none of which can be assured.

    The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normally recurring accruals) considered necessary for a fair presentation have been included.

13

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Polydex Pharmaceuticals Limited
October 31, 2001
Interest Rate Sensitivity

    The table below provides information about the Company's financial instruments that are sensitive to changes in interest rates. All financial instruments are held for other than trading purposes. The Company does not have a material exposure to interest rate risk.

    The table presents principal cash flows and related weighted average interest rates by expected maturity dates.

	Expected Maturity Date
	1/31/02		1/31/03		1/31/04		1/31/05		1/31/06		Thereafter		Total		Fair Value
	(US$ Equivalent)
Assets:
Notes receivable:
Variable rate ($US)	46,017		56,738		60,710		64,960		69,507		354,678		652,611		652,611
Average interest rate	7.00	%	7.00	%	7.00	%	7.00	%	7.00	%	7.00	%	7.00	%
Liabilities:
Long-term debt:
Fixed rate ($US)	49,817		327,667		4,226		—		—		—		381,710		381,710
Average interest rate	9.31	%	9.07	%	9.38	%	—		—		—		9.25	%
Fixed rate ($CDN)	183,768		85,263		86,081		94,156		102,989		102,813		655,070		655,070
Average interest rate	9.03	%	9.23	%	9.00	%	9.00	%	9.00	%	9.00	%	9.04	%
Variable rate ($US)	28,829		(11,536	)	(12,344	)	(13,208	)	(14,132	)	744,594		722,203		722,203
Average interest rate	7.00	%	7.00	%	7.00	%	7.00	%	7.00	%	7.00	%	7.00	%

14

Polydex Pharmaceuticals Limited
October 31, 2001
Exchange Rate Sensitivity

    The table below provides information about the Company's financial instruments that are sensitive to changes in foreign currency exchange rates. All financial instruments are held for other than trading purposes. The Company's major exposure to exchange rate risk is that the Canadian dollar rises dramatically in relation to the U.S. dollar and that this significantly reduces the gross margin experienced at Dextran Products. Management monitors the margin at Dextran to ensure that an acceptable margin level is maintained. Management has the ability, to some extent, to adjust sales prices to maintain an acceptable margin level.

    The table presents principal cash flows and related weighted average interest rates by expected maturity dates.

	Expected Maturity Date
	1/31/02		1/31/03		1/31/04		1/31/05		1/31/06		Thereafter		Total		Fair Value
	(US$ Equivalent)
Liabilities:
Long-term debt:
Fixed rate ($CDN)	183,768		85,263		86,081		94,156		102,989		102,813		655,070		655,070
Average interest rate	9.03	%	9.23	%	9.00	%	9.00	%	9.00	%	9.00	%	9.04	%

15

PART II
OTHER INFORMATION

Item 6.  Exhibits and Reports on Form 8-K.

(a)

Exhibits



3.1

Memorandum of Association of Polydex Pharmaceuticals Limited, as amended to date (filed as Exhibit 3.1 to the Registrant's Annual Report on Form 10-K filed April 30, 1997, and incorporated herein by reference)



3.2

Articles of Association of Polydex Pharmaceuticals Limited, as amended to date (filed as Exhibit 3.2 to the Registrant's Quarterly Report on Form 10-Q filed September 13, 1999, and incorporated herein by reference)



(b)

Reports on Form 8-K

Not applicable.

16

SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: December 14, 2001

POLYDEX PHARMACEUTICALS LIMITED (Registrant)
By:	/s/ GEORGE G. USHER   George G. Usher, Chairman, President and Chief Executive Officer (Principal Executive Officer)
By:	/s/ SHARON L. WARDLAW   Sharon L. Wardlaw, Treasurer, Secretary and Chief Financial and Accounting Officer (Principal Financial Officer)

17

QuickLinks

PART I FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements (unaudited).

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

PART II OTHER INFORMATION

Item 6. Exhibits and Reports on Form 8-K.

SIGNATURES